On the contrary, in tumor cells with RAS mutation, the RAS signaling pathway inhibits TTP activity, resulting in the non-degradation of PD-L1 mRNA and the stability of PD-L1 mRNA is increased. The gene discussed is CD274; the disease is neoplasm.